Sandoz Malaysia Partners to Expand Biosimilars Access

//////

Christine Chong, Country Head, Sandoz Malaysia, Singapore and Brunei, said: “Lymphoma is an area where biologic therapies are critical to patient outcomes, yet many patients face challenges accessing or sustaining treatment. Biosimilars offer the same clinical outcomes as reference biologics, with no meaningful differences in safety or effectiveness, while helping…

Read More